Company intelligence / Profile preview
Hilleman Laboratories
- Ownership
- Private
- Employees
- ~60
- Development stage
- Preclinical
Overview
Hilleman Laboratories develops affordable vaccines and biologics targeting infectious diseases prevalent in low-and middle-income countries. Their pipeline includes heat-stable rotavirus vaccine candidates in advanced development and optimized oral cholera vaccines with cross-protection against ETEC diarrhea. The company focuses on improving access through cost-effective formulations and robust manufacturing processes for use in resource-limited settings
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineBiologic
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Hilleman Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hilleman Laboratories.